BOEHRINGER-INGELHEIM
9.7.2020 16:02:10 CEST | Business Wire | Press release
Results of a global survey of 1,375 adults aged at least 45 years old and living with Chronic Obstructive Pulmonary Disease (COPD) in 11 countries have been published in COPD: Journal of Chronic Obstructive Pulmonary Disease.1 Findings indicate that COPD has a substantial physical and psychosocial impact on patients, particularly those aged 45–54 years old. Compared with older patients (≥65 years old), this group more frequently reported that their COPD has a higher impact on their wellbeing and daily activities, and reported making more frequent adjustments to their activity due to their symptoms.1 Survey results indicate that there are significant quality of life and educational unmet needs, particularly amongst younger people living with COPD.
“This is one of the few surveys that looks at the impact of COPD in different age groups,” said Professor Dr Dekhuijzen, Pulmonologist, Radboud University Medical Center, Nijmegen, The Netherlands. “As healthcare professionals, we have to realise that the same disease has a different impact in younger and older patients, and that the perceived impact has to be addressed to tailor and optimise treatment to suit each patient.”
When looking specifically at the outcomes reported by younger patients (45–54 years old) versus older patients (≥65 years old):
- Younger patients more frequently reported that their COPD ‘extremely’ or ‘very much’ impacts their ability to carry out tasks outside the home (37% vs 22%) and travel long distances (38% vs 18%),1 and they were more than twice as likely to need to plan their day around periods of breathlessness and/or coughing (41% vs 19%)1
- A significantly higher proportion of patients aged 45–54 years old reported “poor” or “very poor” wellbeing (35% vs 28%; P<0.05), and reported feeling “stressed” and “overwhelmed” 1.7 and 2.2 times more frequently (P<0.05), respectively1
- Reliance on physicians was more significant amongst younger patients, who were more than three times more likely to want information to aid them to better manage using their inhaler device (18% vs 58% did not want this type of information)1
“One possible explanation as to why the perceived burden differs strongly is that younger patients are usually more active in terms of their work and social life, and so have differing expectations about what life with COPD will be,” said Nicole Hass, Representative from the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA). “Although more research is needed to better understand why these age differences exist, these findings show we need to make patients more aware of how they can positively impact their disease progression through things like speaking to clinicians about optimal treatment aimed at keeping them active in their daily lives.”
Findings reinforce the need for HCPs and COPD patients, particularly younger ones, to work towards optimal treatment management and therapy aimed at improving symptoms and lessening the impact of the disease on patients’ quality of life. According to Dr. Paola Casarosa, Head of Global Therapeutic Areas at Boehringer Ingelheim, “Overall, the results of this survey align with our ongoing efforts as an organisation, highlighting the importance of optimising treatment and helping patients to maintain active lives.”
Intended audiences:
Global and local, in-country medical media.
This press release is issued from our Corporate Headquarters in Ingelheim, Germany, and is intended to provide information about the results of our global COPD patient survey.
For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/perceived-burden-copd-higher-younger-patients
Boehringer Ingelheim
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005650/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience23.2.2026 15:13:00 CET | Press release
Express Access, Party Favors, and Private Room with Decorations and Ghirardelli Ice Cream Sundaes Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95th anniversary celebrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223161708/en/ The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience “From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-fa
Xsolla Co-Sponsors Gamescom Dev Leadership Summit in Lisbon, Bringing Together Gaming Industry Leaders to Shape the Future of Game Development23.2.2026 15:00:00 CET | Press release
Platform Supporting 1,500+ Game Developers Across 200+ Geographies to Host Networking Dinner and Co-Moderate Strategic Roundtable at Premier European Gaming Executive Summit Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its co-sponsorship of the Gamescom Dev Leadership Summit Lisbon, taking place February 24-26 at SUD Lisboa in Portugal. The event brings together gaming industry executives, studio founders, and business leaders to explore opportunities and innovations shaping the future of game development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223253705/en/ Graphic: Xsolla As part of its sponsorship, Xsolla will host the summit's Wednesday evening networking dinner and co-moderate a strategic roundtable session focused on business models and sustainable growth in the gaming industry. "We're seeing incredible innovation from studios acro
CoolMPS™ 600: Accurate and Affordable Long MPS/NGS Reads on a Mid-Throughput Platform23.2.2026 15:00:00 CET | Press release
Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026. Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is utilizing the company’s proprietary antibody-based CoolMPS™ chemistry combined with DNBSEQ™, a real PCR-free DNA nanoarray technology. Separately, Swiss Rockets AG announced that it has entered into a definitive agreement to acquire 100% ownership of Complete Genomics. CoolMPS 600 enables cost-effective extended single-end sequencing to 600 bases (SE600) while maintaining high base accuracy. The system is designed to support advanced whole-genome sequencing (WGS) with improved mapping accuracy across complex genomic regions, including better detection of structural variants. It also enables full length transcriptomes and more infor
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 14:08:00 CET | Press release
Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.busine
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 14:00:00 CET | Press release
DoD customers can now leverage Armis Centrix™ with enhanced security controls and connectivity Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
